Yamauchi K, Nakatsuji H, Kamishima T, Koseki Y, Kubo M, Kasai H
Sci Rep. 2024; 14(1):4106.
PMID: 38374237
PMC: 10876936.
DOI: 10.1038/s41598-024-53888-2.
Jeon J, Kim J, Kang S, Lee J, Kim S
Mar Biotechnol (NY). 2008; 11(3):307-16.
PMID: 18814017
DOI: 10.1007/s10126-008-9145-2.
Puustjarvi T, Terasvirta M, Nurmenniemi P, Lokkila J, Uusitalo H
Graefes Arch Clin Exp Ophthalmol. 2006; 244(12):1633-7.
PMID: 16715252
DOI: 10.1007/s00417-006-0360-0.
Sanchez Navarro A, Colino Gandarillas C, Alvarez Lerma F, Menacho Y, Dominguez-Gil A
Clin Pharmacokinet. 2005; 44(6):627-35.
PMID: 15910010
DOI: 10.2165/00003088-200544060-00004.
Geerdes-Fenge H, Wiedersich A, Wagner S, Lehr K, Koeppe P, Lode H
Antimicrob Agents Chemother. 2000; 44(12):3478-80.
PMID: 11083664
PMC: 90229.
DOI: 10.1128/AAC.44.12.3478-3480.2000.
Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Chien S, Wong F, Fowler C, Williams R, Nayak R, Chow A
Antimicrob Agents Chemother. 1998; 42(4):885-8.
PMID: 9559801
PMC: 105560.
DOI: 10.1128/AAC.42.4.885.
Absorption of ofloxacin isomers in the rat small intestine.
Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R
Antimicrob Agents Chemother. 1997; 41(10):2274-7.
PMID: 9333061
PMC: 164106.
DOI: 10.1128/AAC.41.10.2274.
Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
Chien S, Rogge M, Gisclon L, Curtin C, Wong F, Natarajan J
Antimicrob Agents Chemother. 1997; 41(10):2256-60.
PMID: 9333057
PMC: 164102.
DOI: 10.1128/AAC.41.10.2256.
Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
Lee L, Hafkin B, Lee I, Hoh J, Dix R
Antimicrob Agents Chemother. 1997; 41(10):2196-200.
PMID: 9333047
PMC: 164092.
DOI: 10.1128/AAC.41.10.2196.
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File Jr T, Segreti J, Dunbar L, Player R, Kohler R, Williams R
Antimicrob Agents Chemother. 1997; 41(9):1965-72.
PMID: 9303395
PMC: 164046.
DOI: 10.1128/AAC.41.9.1965.
Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien S, Chow A, Rogge M, Williams R, Hendrix C
Antimicrob Agents Chemother. 1997; 41(8):1765-9.
PMID: 9257757
PMC: 164001.
DOI: 10.1128/AAC.41.8.1765.
Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.
Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R
Antimicrob Agents Chemother. 1996; 40(9):2126-30.
PMID: 8878593
PMC: 163485.
DOI: 10.1128/AAC.40.9.2126.
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.
Fuchs P, Barry A, Brown S
Antimicrob Agents Chemother. 1996; 40(7):1633-9.
PMID: 8807053
PMC: 163386.
DOI: 10.1128/AAC.40.7.1633.
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T
Antimicrob Agents Chemother. 1996; 40(5):1201-7.
PMID: 8723467
PMC: 163292.
DOI: 10.1128/AAC.40.5.1201.
Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme.
Froelich-Ammon S, McGuirk P, Gootz T, Jefson M, Osheroff N
Antimicrob Agents Chemother. 1993; 37(4):646-51.
PMID: 8388196
PMC: 187729.
DOI: 10.1128/AAC.37.4.646.
Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N, Rolston K, Ho D, LeBlanc B, Bodey G
Antimicrob Agents Chemother. 1994; 38(4):848-52.
PMID: 8031057
PMC: 284553.
DOI: 10.1128/AAC.38.4.848.
Activity of levofloxacin in a murine model of tuberculosis.
Klemens S, Sharpe C, Rogge M, Cynamon M
Antimicrob Agents Chemother. 1994; 38(7):1476-9.
PMID: 7979275
PMC: 284579.
DOI: 10.1128/AAC.38.7.1476.
Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.
Davis R, Bryson H
Drugs. 1994; 47(4):677-700.
PMID: 7516863
DOI: 10.2165/00003495-199447040-00008.
Enantioselective disposition of ofloxacin in humans.
Okazaki O, Kojima C, Hakusui H, Nakashima M
Antimicrob Agents Chemother. 1991; 35(10):2106-9.
PMID: 1759834
PMC: 245334.
DOI: 10.1128/AAC.35.10.2106.
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin.
Fu K, Lafredo S, Foleno B, Isaacson D, Barrett J, Tobia A
Antimicrob Agents Chemother. 1992; 36(4):860-6.
PMID: 1503449
PMC: 189464.
DOI: 10.1128/AAC.36.4.860.